Skip to main content

01-09-2023 | Semaglutide | News


FDA approves high-dose semaglutide for adolescents with obesity

Author: Lynda Williams


medwireNews: The US FDA has granted approval for the use of semaglutide at a dose of 2.4 mg/week for the treatment of obesity in children aged 12 years or older with a BMI in the 95th percentile or higher for their age and sex.

The announcement follows findings from the STEP TEENS trial which demonstrated substantial weight loss with the glucagon-like peptide-1 receptor agonist compared with placebo.

Semaglutide 2.4 mg has previously been approved for use in adults with a BMI above 30 kg/m2 and those with a BMI above 27 kg/m2 and a weight-related comorbidity, such as type 2 diabetes or hypertension.

The agent carries a black box warning against its use in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.

medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2023 Springer Healthcare Ltd, part of the Springer Nature Group


Be confident that your patient care is up to date

Medicine Matters is being incorporated into Springer Medicine, our new medical education platform. 

Alongside the news coverage and expert commentary you have come to expect from Medicine Matters diabetes, Springer Medicine's complimentary membership also provides access to articles from renowned journals and a broad range of Continuing Medical Education programs. Create your free account »